|Articles|November 1, 2003
- Pharmaceutical Technology-11-01-2003
- Volume 2003 Supplement
- Issue 5
21 CFR Part 11: Where Are We Now?
Author(s)William Goebel
FDA's revised guidance on 21 CFR Part 11 offers relief to the regulated industry by providing for enforcement discretion and suggesting a risk-based approach to compliance.
Advertisement
Articles in this issue
about 22 years ago
Improving the Management of Batch Recordsabout 22 years ago
Understanding Data, Symbol, and Technology Optionsabout 22 years ago
Web Services in Pharmaceutical Manufacturingabout 22 years ago
Integrated Compliance ManagementNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
3
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
4
European Parliament Revamps Pharmaceutical Policy Framework
5
